ABCD-GENE Score Calculator – Clopidogrel Response and PCI Ischemic Risk

Clinical calculation support · Verify results before clinical use

ABCD-GENE Score

Estimate the likelihood of high platelet reactivity (HPR) and reduced clopidogrel effectiveness using clinical factors and CYP2C19 loss-of-function genotype.

—Points
A

Age

Enter age in completed years. The score assigns points only when age is greater than 75 years.

+4 points if >75 y
Adult patients; enter a whole number from 18 to 120.
B

Body Mass Index (BMI)

BMI greater than 30 kg/m² contributes to the score.

+4 points if >30
Enter BMI in kg/m². Use the measured value; do not round across the 30 kg/m² threshold.
C

Renal Function (eGFR)

The score defines the CKD component as eGFR below 60 mL/min/1.73 m².

+3 points if <60
Enter eGFR in mL/min/1.73 m². This is the score's operational threshold, not a standalone CKD diagnosis.
D

Diabetes Mellitus

Select whether the patient has diabetes mellitus.

+3 points if present
G

CYP2C19 Loss-of-Function (LOF) Alleles

Select the number of CYP2C19 no-function alleles reported by a validated genotyping test.

0 / +6 / +24 points
Use the laboratory's CYP2C19 phenotype/genotype interpretation. Do not infer LOF allele count from ethnicity or clinical characteristics.
—ABCD-GENE
Score interpretation
Complete all fields
Enter the clinical characteristics and CYP2C19 LOF allele count to calculate the score.
Clinical context The score will be interpreted after all required inputs are provided.

A score ≥10 is the original proposed threshold associated with increased likelihood of HPR on clopidogrel. It is not an absolute probability of HPR, myocardial infarction, stent thrombosis, or death.

About the ABCD-GENE Score

The ABCD-GENE score combines four clinical factors with CYP2C19 loss-of-function genotype to identify patients who may have high platelet reactivity while receiving clopidogrel. It was developed and validated in patients treated with clopidogrel, including patients with myocardial infarction and those undergoing PCI.

Score components

ComponentDefinitionPoints
Age>75 years+4
BMI>30 kg/m²+4
Chronic kidney diseaseeGFR <60 mL/min/1.73 m²+3
Diabetes mellitusPresent+3
CYP2C19 genotype1 LOF allele+6
CYP2C19 genotype2 LOF alleles+24

Interpretation threshold

Score <10: below the proposed high-score threshold.

Score ≥10: associated with greater likelihood of HPR and increased ischemic event risk in studied clopidogrel-treated populations. The score's discrimination for clinical outcomes is modest; it should not be used as a stand-alone clinical risk model or to calculate an individual's absolute event probability.

Important use considerations

  • Use the score only when CYP2C19 genotype information is available; the genetic component is integral to the score.
  • The score is an adjunct for assessing clopidogrel response, not a substitute for platelet-function testing when clinically indicated.
  • Clinical decisions after ACS or PCI should incorporate ischemic risk, bleeding risk, contraindications, concomitant therapy, and current guideline recommendations.

References

Angiolillo DJ, Capodanno D, Danchin N, et al. Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel: The ABCD-GENE Score. JACC Cardiovasc Interv. 2020;13(5):606–617. DOI: 10.1016/j.jcin.2020.01.226.
Lee CR, Luzum JA, Sangkuhl K, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959–967. DOI: 10.1002/cpt.2526.
Saito Y, Nishi T, Wakabayashi S, et al. Validation of the ABCD-GENE score to identify high platelet reactivity in east Asian patients undergoing percutaneous coronary intervention. Int J Cardiol. 2021;327:15–18. DOI: 10.1016/j.ijcard.2020.11.022.
Thomas CD, et al. Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score. J Am Coll Cardiol. 2024;83(15):1370–1381. DOI: 10.1016/j.jacc.2024.02.015.
Dello Russo A, et al. CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). Br J Clin Pharmacol. 2026;92(2):329–347. DOI: 10.1002/bcp.70370.
Clinical disclaimer: This calculator is an educational clinical decision-support aid. The ABCD-GENE score estimates the likelihood of high platelet reactivity on clopidogrel and identifies a group associated with higher ischemic risk in selected study populations; it does not diagnose clopidogrel resistance or provide an individualized absolute risk estimate. Do not initiate, discontinue, or switch antiplatelet therapy solely on the basis of this score. Consider the patient's clinical presentation, PCI details, bleeding risk, drug interactions, adherence, CYP2C19 test methodology, contraindications, and applicable local guidelines.